Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Clinical trial NCT05036798 · UNKNOWN
Trial details
- NCT number
- NCT05036798
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-17
- Primary completion
- 2022-07-02
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.